Pliant Common Stock from 2010 to 2025

PLRX Stock

USD 1.55 0.03 1.90%

Pliant Therapeutics Common Stock yearly trend continues to be fairly stable with very little volatility. Common Stock will likely drop to 3,575 in 2025. During the period from 2010 to 2025, Pliant Therapeutics Common Stock regression line of annual values had r-squared of 0.63 and arithmetic mean of 2,342. View All Fundamentals

Common Stock

First Reported

2019-03-31

Previous Quarter

6 K

Current Value

6 K

Quarterly Volatility

1.7 K

Covid

Check Pliant Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pliant Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 22.1 M, Net Interest Income of 19 M or Interest Income of 22.1 M, as well as many indicators such as Price To Sales Ratio of 636, Dividend Yield of 0.0 or PTB Ratio of 2.75. Pliant financial statements analysis is a perfect complement when working with Pliant Therapeutics Valuation or Volatility modules.

Check out the analysis of Pliant Therapeutics Correlation against competitors.

For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

Latest Pliant Therapeutics' Common Stock Growth Pattern

Below is the plot of the Common Stock of Pliant Therapeutics over the last few years. It is Pliant Therapeutics' Common Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pliant Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Common Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Common Stock

Timeline

Pliant Common Stock Regression Statistics

	Arithmetic Mean	2,342
	Geometric Mean	1,734
	Coefficient Of Variation	86.53
	Mean Deviation	1,678
	Median	1,000.00
	Standard Deviation	2,027
	Sample Variance	4.1M
	Range	5.9K
	R-Value	0.80
	Mean Square Error	1.6M
	R-Squared	0.63
	Significance	0.0002
	Slope	338.71
	Total Sum of Squares	61.6M

Pliant Common Stock History

	2025	3575.0
	2024	6900.0
	2023	6000.0
	2022	5000.0
	2020	3000.0

Other Fundumenentals of Pliant Therapeutics

	Common Stock Total Equity
	Common Stock Shares Outstanding

Pliant Therapeutics Common Stock component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Debt	Deferred Long Term Liab	Net Invested Capital	Capital Stock	Net Working Capital	Capital Surpluse	Short Term Debt	Long Term Debt	Long Term Debt Total
Total Assets		0.98	0.92	-0.83	0.74	0.55	0.47	1.0	0.95	0.59	0.61	0.88	0.98	-0.92	0.99	0.84	-0.58	0.45	-0.36
Total Stockholder Equity	0.98		0.93	-0.78	0.7	0.48	0.28	0.98	0.94	0.55	0.68	0.82	1.0	-0.93	0.99	0.8	-0.53	0.38	-0.31
Net Tangible Assets	0.92	0.93		-0.88	0.69	0.49	0.3	0.91	0.91	0.6	0.77	0.78	0.95	-0.98	0.92	0.79	-0.59	0.55	-0.58
Retained Earnings	-0.83	-0.78	-0.88		-0.84	-0.32	-0.52	-0.82	-0.89	-0.5	-0.59	-0.66	-0.81	0.8	-0.83	-0.88	0.82	-0.77	0.77
Accounts Payable	0.74	0.7	0.69	-0.84		0.2	0.46	0.73	0.83	0.49	0.39	0.57	0.72	-0.66	0.72	0.78	-0.83	0.78	-0.5
Net Receivables	0.55	0.48	0.49	-0.32	0.2		0.53	0.56	0.36	0.38	-0.01	0.75	0.49	-0.51	0.52	0.19	-0.23	0.19	-0.21
Total Liab	0.47	0.28	0.3	-0.52	0.46	0.53		0.45	0.42	0.4	-0.06	0.61	0.3	-0.27	0.37	0.46	-0.4	0.51	-0.38
Total Current Assets	1.0	0.98	0.91	-0.82	0.73	0.56	0.45		0.94	0.58	0.61	0.87	0.98	-0.91	0.99	0.82	-0.56	0.42	-0.35
Common Stock	0.95	0.94	0.91	-0.89	0.83	0.36	0.42	0.94		0.51	0.7	0.8	0.94	-0.88	0.94	0.95	-0.62	0.63	-0.42
Property Plant Equipment	0.59	0.55	0.6	-0.5	0.49	0.38	0.4	0.58	0.51		0.42	0.71	0.59	-0.72	0.52	0.31	-0.25	0.24	-0.27
Net Debt	0.61	0.68	0.77	-0.59	0.39	-0.01	-0.06	0.61	0.7	0.42		0.43	0.7	-0.77	0.62	0.67	-0.13	0.33	-0.32
Deferred Long Term Liab	0.88	0.82	0.78	-0.66	0.57	0.75	0.61	0.87	0.8	0.71	0.43		0.83	-0.83	0.83	0.65	-0.36	0.4	-0.25
Net Invested Capital	0.98	1.0	0.95	-0.81	0.72	0.49	0.3	0.98	0.94	0.59	0.7	0.83		-0.96	0.99	0.81	-0.55	0.42	-0.36
Capital Stock	-0.92	-0.93	-0.98	0.8	-0.66	-0.51	-0.27	-0.91	-0.88	-0.72	-0.77	-0.83	-0.96		-0.91	-0.71	0.49	-0.45	0.46
Net Working Capital	0.99	0.99	0.92	-0.83	0.72	0.52	0.37	0.99	0.94	0.52	0.62	0.83	0.99	-0.91		0.83	-0.6	0.42	-0.37
Capital Surpluse	0.84	0.8	0.79	-0.88	0.78	0.19	0.46	0.82	0.95	0.31	0.67	0.65	0.81	-0.71	0.83		-0.61	0.69	-0.46
Short Term Debt	-0.58	-0.53	-0.59	0.82	-0.83	-0.23	-0.4	-0.56	-0.62	-0.25	-0.13	-0.36	-0.55	0.49	-0.6	-0.61		-0.72	0.75
Long Term Debt	0.45	0.38	0.55	-0.77	0.78	0.19	0.51	0.42	0.63	0.24	0.33	0.4	0.42	-0.45	0.42	0.69	-0.72		-0.73
Long Term Debt Total	-0.36	-0.31	-0.58	0.77	-0.5	-0.21	-0.38	-0.35	-0.42	-0.27	-0.32	-0.25	-0.36	0.46	-0.37	-0.46	0.75	-0.73

Click cells to compare fundamentals

About Pliant Therapeutics Financial Statements

Pliant Therapeutics investors use historical fundamental indicators, such as Pliant Therapeutics' Common Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pliant Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Common Stock	6.9 K	3.6 K
Common Stock Total Equity	5.8 K	6 K
Common Stock Shares Outstanding	60.5 M	44.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pliant Common Stock from 2010 to 2025

Latest Pliant Therapeutics' Common Stock Growth Pattern

Pliant Common Stock Regression Statistics

Pliant Common Stock History

Other Fundumenentals of Pliant Therapeutics

Pliant Therapeutics Common Stock component correlations

About Pliant Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Pliant Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY